Denali Therapeutics Inc.DNLINASDAQ

Revenue (LTM)

Net Income (LTM)

$-513M

-21.2% YoY

Free Cash Flow

$-422M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.4B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	49	108↑122.9%	331↑204.7%	0	0
Gross Profit	49	108↑122.9%	331↑204.7%	0	-11
Operating Income	-296	-341↓15.2%	-197↑42.3%	-487↓147.8%	-555↓14.0%
Net Income	-291	-326↓12.2%	-145↑55.5%	-423↓191.1%	-513↓21.2%
EBITDA	-287	-330↓15.0%	-180↑45.5%	-493↓173.9%	-498↓1.0%
EPS Diluted	-2.39	-2.60↓8.8%	-1.06↑59.2%	-2.57↓142.5%	-2.97↓15.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	293	218↓25.7%	127↓41.7%	175↑37.6%	205↑17.4%
Total Current Assets	897	1,372↑52.9%	1,064↓22.5%	864↓18.8%	901↑4.2%
Total Assets	1,404	1,460↑4.0%	1,154↓21.0%	1,374↑19.1%	1,145↓16.7%
Total Current Liabilities	378	364↓3.8%	78↓78.6%	102↑31.1%	98↓3.8%
Total Liabilities	442	418↓5.4%	123↓70.6%	144↑17.5%	131↓9.3%
Total Equity	962	1,042↑8.3%	1,031↓1.1%	1,230↑19.3%	1,014↓17.6%
Total Debt	64	60↓5.7%	52↓13.4%	49↓6.8%	42↓13.2%
Net Debt	-229	-158↑31.3%	-75↑52.5%	-126↓68.6%	-163↓29.1%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-211	-245↓15.8%	-358↓46.3%	-348↑2.9%	-413↓18.7%
Capital Expenditure	-9	-18↓109.8%	-13↑27.4%	-16↓23.0%	-10↑40.3%
Free Cash Flow	-220	-263↓19.4%	-371↓41.3%	-364↑2.0%	-422↓16.1%
Stock-Based Comp	85	100↑17.1%	108↑8.3%	103↓4.8%	100↓3.2%
Net Change in Cash	-214	-75↑64.7%	-91↓20.6%	48↑152.6%	32↓33.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance